Amarantus Bioscience Holdings, Inc. (OTCMKTS:AMBS) Lifted on Super Bowl Events Publicity
Amarantus Bioscience Holdings, Inc. (OTCMKTS:AMBS) is yet another pharmaceutical ticker that awoke in 2014, and quietly went up, behind the screen of roaring cannabis stocks. AMBS had its periods of temporary depression, but pharmaceutical companies are usually forward-looking, and AMBS has arrived into a period of new hope. On Tuesday, AMBS added more than 11% to stand at $0.123, on buying volumes of above $2.69 million. 
AMBS has not been promoted since the fall of last year, and the events propping up the stock are a series of press releases, plus the expectation that commercial sale of the LymPro and other therapies would finally begin in 2014. AMBS is still not considered a stock so much for trading as it is for holding, in expectation of future gains. 
In the shorter term, AMBS will be expecting the results of a specialized and highly public panel, as part of the Super Bowl Event Series. In a panel featuring former NFL greats Clinton Portis, Jeremy Shockey, Antonio Pierce and current NFL players Green Bay Packer Jermichael Finley and Seattle Seahawk Sidney Rice, AMBS would be presenting its potential in medical science targeted to degenerative diseases. The event would be held at the United Nations Headquarters in New York. AMBS is devoted to finding treatments for concussions and similar sports injuries, as it targets its drugs to the nervous system.
The use of publicity awakened long-term drifter Advanced Cell Technology, Inc. (OTCMKTS:ACTC), as the ticker is also carried on expectations of future development. ACTC will be benefiting from an upcoming documentary, where founder Dr. Rober Lanza will outline the science of stem cells and their therapeutic potential. ACTC added more than 18% to stand at $0.0875 on buying volumes a bit lower that Monday’s, at $5.34 million.
Nuvilex, Inc. (OTCMKTS:NVLX) was yet another strong climber which even mentioned uplisting, but the new week did not turn so profitable, as Tuesday wiped out more than 12% to a price of $0.18, on heavy selling above $5.22 million. In 2014, buying for NVLX still outstrips the selling days, and underlines the periods of hopefulness that tickers in this sector enjoy.
While all seems right for AMBS, a recent S-1 form revealed that the company has registered 172,466,494 shares at $0.001 par value, with potential resale upon the conversion of debentures from third parties. Given that AMBS has around 551 million shares outstanding, the impact of that amount of shares spilled onto the market may be a depressed price, and in any case, significant dilution.
Pharmaceutical businesses may show signs of thriving and even great exuberance, but keep in mind that those companies often gap downward, as investors are easily disappointed by a regular infusion of hopeful, forward-looking statements. Avoid overinvesting in AMBS, despite the relatively accessible price, and be aware that news and PR may be lifting the shares in disproportion, at least until the company gives some proof of the success of its commercial products in the coming quarters.
